Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder

NCT01844115 PHASE3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD).

Details

Lead sponsor	Forest Laboratories
Phase	PHASE3
Status	COMPLETED
Enrolment	415
Start date	Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 31 2014 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Generalized Anxiety Disorder

Interventions

• Placebo
• Vilazodone

Countries

United States